http://www.fpnotebook.com/
Menopause
Aka: Menopause, Perimenopause
- Symptoms: Perimenopause (lasts 3-8 years)
- Disturbance in menstrual pattern
- Shorter menstrual interval
- Heavier menstrual flow
- Hot Flashes (50-75% of women)
- Atrophic conditions (responds to Estrogen)
- Vaginal Mucosa (Atrophic Vaginitis)
- Vaginitis or vaginal Pruritus
- Dyspareunia
- Urethritis
- Dysuria, urgency, or urinary frequency
- Recurrent Urinary Tract Infection
- Neuropsychological changes
- Major Depression
- Estrogen Replacement efficacious as Antidepressant
- Soares (2001) Arch Gen Psychiatry 58:529-34
- Insomnia
- Hippocampus changes
- Decreased memory
- Decreased learning
- Decreased navigation or way finding
- Testosterone Deficiency (worse in surgical Menopause)
- Decreased energy and sense of well being
- Decreased sexual desire, arousability, and orgasm
- Decreased clitoral sensitivity
- Decreased nipple sensitivity
- Thinning of pubic hair
- Labs
- Follicle Stimulating Hormone (FSH)
- Not necessary to confirm diagnosis
- May be indicated for perimenopausal women age <45
- FSH >25 mIU/ml confirms Perimenopause or Menopause
- Measure on any day if patient is not having Menses
- Measure on Day 3 of cycle in menstruating women
- Measure Day 6-7 of Oral ContraceptivePlacebo week
- Confirms Birth Control no longer needed
- Thyroid Stimulating Hormone (TSH)
- Consider for atypical or young presentation
- Vasomotor (hot flash) symptoms predominate
- Vaginal pH
- pH > 4.5 indicates Menopause
- Women without Vaginitis and not receiving HRT
- pH <4.5
- Can be used to monitor for adequate HRT response
- References
- Roy (2004) Am J Obstet Gynecol 190:1272-7
- Diagnosis
- Serum FSH level are not necessary in age over 45 years
- Perimenopause: Hot Flashes and irregular Menses
- Menopause: Hot Flashes and no Menses for 6 months
- Management: General Approach
- See symptom management below for Menopause and Perimenopause
- Osteoporosis Prevention
- See Osteoporosis and Osteoporosis Management
- Calcium Supplementation at 1500 mg per day
- Vitamin D Supplementation 800-1000 IU per day
- Cardiovascular Disease Prevention
- See Cardiac Risk Management
- See Exercise in the Elderly
- Tobacco Cessation
- Cancer Prevention
- Breast Cancer Screening
- Cervical Cancer Screening
- Colorectal Cancer Screening
- Immunization
- Management: Menopausal Symptom Management (and Osteoporosis Prevention)
- See alternatives for Vasomotor Symptoms of Menopause
- Estrogen Replacement Therapy
- Weigh risks (CAD, DVT, CVA, Breast Cancer) versus benefits (Osteoporosis, Hot Flashes)
- See Cardiac Risk Management
- See Estrogen Replacement for a general overview of risks, benefits and protocols
- See Specific Estrogen Replacement Options
- Continuous Estrogen Replacement
- Sequential Estrogen Replacement
- Vaginal Estrogen
- Transdermal Estrogen
- Management: Perimenopausal Symptom management
- See Vasomotor Symptoms of Menopause
- Agents
- Provera 5-10 mg for 12 days per month
- Prevents Endometrial Hyperplasia
- Oral Contraceptives (OCP)
- Choose continuous low Estrogen option (e.g. Lo Loestrin Fe)
- Levonorgestrel IUD (Mirena)
- Stops Menstrual Bleeding but risk of atrophy
- Sequential Hormone Replacement
- Evaluating end of Perimenopause for women on OCPs
- Identify when to switch to postmenopause management
- Obtain Serum FSH on 6th day of OCPs Placebo pills
- Menopause suggested by FSH > 30 IU/L
- Management: Adjunctive Therapy
- Consider Androgen Replacement in Women
- Testosterone Replacement in Women
- DHEA Replacement in Women
- Combination Preparations
- E2P4T (Estrogen, Progesterone, Testosterone)
- Available from compounding pharmacies
- DHEA-S (see DHEA-S Replacement in Women)
- Used with the E2P4T
- Management: Other agents
- See Vasomotor Symptoms of Menopause
- Complimentary and Alternative Medicine (Variable efficacy)
- Phytoestrogens
- Dong Quai
- Yam extract
- Black Cohosh
- New agents
- Amberen
- Combination of multiple components (calcium, Magnesium, Vitamin E, Zinc, Ammonium Succinate)
- No evidence of benefit and expensive
- (2013) Presc Lett 20(2): 11
- References
- Greenblatt (1972) J Am Geriatr Soc 20:49
- Orentreich (1984) J Clin Endocrinol Metab 59:551
- Seeman (1997) Am J Psychiatry 154:1641-7
- Shifren (2000) N Engl J Med 343:682-8
- Shuer (2001) CMEA Medicine Lecture, San Diego